Chemclin Diagnostics Co., Ltd. (SHA:688468)
China · Delayed Price · Currency is CNY 6.59
-0.10 (-1.49%)
Oct 8, 2026, 2:50 PM CST
Chemclin Diagnostics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 322.53 | 332.68 | 436.29 | 445.34 | 465.27 | 470.77 | |
Revenue Growth | -14.07% | -23.75% | -2.03% | -4.28% | -1.17% | 12.57% |
Cost of Revenue | 126.8 | 119.09 | 115.35 | 110.56 | 121.11 | 119.84 |
Gross Profit | 195.73 | 213.58 | 320.94 | 334.78 | 344.16 | 350.94 |
Selling, General & Admin | 95.81 | 104.78 | 134.38 | 133.41 | 135.17 | 143.23 |
Research & Development | 73.65 | 72.7 | 73.74 | 65.14 | 68.36 | 66.78 |
Other Operating Expenses | 8.72 | 4.94 | 5.38 | 5.03 | 5.49 | 3.66 |
Operating Expenses | 178.08 | 182.44 | 213.3 | 203.17 | 209.05 | 213.82 |
Operating Income | 17.65 | 31.14 | 107.65 | 131.61 | 135.11 | 137.12 |
Interest Expense | -5.88 | -6.41 | -5.24 | -0.47 | -0.52 | -0.73 |
Interest & Investment Income | 17.29 | 18.81 | 19.79 | 22.04 | 25.03 | 18.29 |
Currency Exchange Gain (Loss) | -0.24 | -0.11 | 0.07 | 0.08 | 0.4 | -0.13 |
Other Non Operating Income (Expenses) | -0.75 | -0.68 | -0.09 | -0.15 | -0.08 | -0.42 |
EBT Excluding Unusual Items | 28.07 | 42.75 | 122.18 | 153.12 | 159.93 | 154.13 |
Gain (Loss) on Sale of Investments | 1.53 | 1.22 | - | - | - | - |
Gain (Loss) on Sale of Assets | 0.68 | 0.15 | 0.06 | 0.14 | -0.62 | -0.64 |
Asset Writedown | -2.13 | -3.05 | -3.67 | -2.8 | -1.46 | -0.32 |
Other Unusual Items | 12.29 | 8.74 | 19.35 | 15.66 | 19.51 | 9.02 |
Pretax Income | 40.43 | 49.82 | 137.92 | 166.12 | 177.37 | 162.19 |
Income Tax Expense | 5.32 | 5.91 | 10.84 | 18.75 | 24.74 | 19.43 |
Net Income | 35.11 | 43.91 | 127.07 | 147.37 | 152.63 | 142.76 |
Net Income to Common | 35.11 | 43.91 | 127.07 | 147.37 | 152.63 | 142.76 |
Net Income Growth | -53.05% | -65.44% | -13.77% | -3.44% | 6.91% | 21.99% |
Shares Outstanding (Basic) | 391 | 399 | 397 | 398 | 402 | 386 |
Shares Outstanding (Diluted) | 391 | 399 | 397 | 398 | 402 | 386 |
Shares Change | -1.93% | 0.53% | -0.30% | -0.83% | 4.10% | 8.80% |
EPS (Basic) | 0.09 | 0.11 | 0.32 | 0.37 | 0.38 | 0.37 |
EPS (Diluted) | 0.09 | 0.11 | 0.32 | 0.37 | 0.38 | 0.37 |
EPS Growth | -52.12% | -65.63% | -13.51% | -2.63% | 2.70% | 12.12% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 73.19 | 24.01 | 60.46 | -128.32 | 119.28 | 116.31 |
Free Cash Flow Per Share | 0.19 | 0.06 | 0.15 | -0.32 | 0.30 | 0.30 |
Dividend Per Share | - | - | 0.125 | 0.125 | 0.347 | 0.170 |
Dividend Growth | - | - | 0% | -63.98% | 104.12% | - |
Gross Margin | 60.69% | 64.20% | 73.56% | 75.17% | 73.97% | 74.54% |
Operating Margin | 5.47% | 9.36% | 24.67% | 29.55% | 29.04% | 29.13% |
Profit Margin | 10.88% | 13.20% | 29.13% | 33.09% | 32.80% | 30.32% |
Free Cash Flow Margin | 22.69% | 7.22% | 13.86% | -28.81% | 25.64% | 24.71% |
EBITDA | 61.39 | 77.91 | 154.01 | 168.77 | 175.19 | 179.97 |
EBITDA Margin | 19.04% | 23.42% | 35.30% | 37.90% | 37.65% | 38.23% |
D&A For EBITDA | 43.74 | 46.77 | 46.37 | 37.16 | 40.08 | 42.84 |
EBIT | 17.65 | 31.14 | 107.65 | 131.61 | 135.11 | 137.12 |
EBIT Margin | 5.47% | 9.36% | 24.67% | 29.55% | 29.04% | 29.13% |
Effective Tax Rate | 13.17% | 11.86% | 7.86% | 11.29% | 13.95% | 11.98% |
Revenue as Reported | 322.53 | 332.68 | 436.29 | 445.34 | 465.27 | 470.77 |
Advertising Expenses | - | - | - | 6.63 | 4.1 | 6.76 |